According to the National Institutes of Health (NIH), a “rare cancer” is one with a prevalence of fewer than 200,000 affected individuals in the United States. Many rare cancers are drastically underfunded, leaving patients with limited treatment options. Memorial Sloan-Kettering Cancer Center, the nation’s preeminent center for research and treatment, is committed to changing that.
100% of the funds go directly to Memorial Sloan-Kettering Cancer Center and are allocated within six months of each event. The donations help fund the most promising research and clinical trials, and have led to better treatments for cancer patients worldwide. If you want to actively fight cancer, you should join the battle with us.
Take action against rare cancers.JOIN THE BATTLE
Since its inception in 2007, Cycle for Survival has raised over $31.5 million dollars for rare cancer research and funded 53 clinical trials and research studies. Cycle’s direct funding has drastically reduced the time it takes for treatments to reach patients — in some cases cutting the span from years to months.
Cancer Biology and Genetics Program scientists are working to determine whether inhibiting a gene called CSF-1R might suppress the development of certain brain tumors called gliomas.
Investigators in the Cancer Biology and Genetics Program are studying residual and recurrent glioma to learn more about how brain tumor cells manage to resist conventional therapies.
Physicians in the Gynecologic Medical Oncology Service are employing comprehensive molecular profiling of low-grade serous and serous borderline ovarian cancer.
Radiologists are working to develop innovative ways to measure the effects of new therapies on pancreatic neuroendocrine tumors
Scientists in the Molecular Biology Program are exploring the role of a promising new drug, called PDO331991, in the treatment of glioma.
Physicians in the Lymphoma Service are studying innovative new therapies for T-cell lymphomas.
A study conducted within the sarcoma consortium (a collaboration of 20 clinical centers) has shown that a novel combination of two drugs controls tumor growth better than either drug administered alone. And based on preclinical data made possible by Cycle funds, MSKCC has been approved to begin the first clinical trial to test a drug that inhibits a protein called Aurora Kinase A. The study will have the support of the NCI and will be brought directly into the sarcoma consortium.
Physicians in the Head and Neck Medical Oncology Service are conducting a Phase II study of a drug, called MK-2206, in patients with a progressive recurrent/metastatic adenoid cystic carcinoma, a rare cancer that often occurs in the head and neck. .
Physicians in the Department of Pathology are using whole genome sequencing a process that determines the complete DNA sequence of an organism’s genome at a single time to study a rare but aggressive cancer called urothelial neoplasm.
All returning users and past participants please enter your login info.
We show that you are registered for multiple events.
Please select the event you would like to manage below.